Contact Us  |  Search: 

A new treatment option for patients who have androgen-resistant prostate cancer (ARPC) is now available at Maimonides Cancer Center. Maimonides has been selected as a participant in an international trial of abiraterone acetate, a brand new hormonal treatment shown in a recent phase III trial to extend survival for patients with chemotherapy-resistant disease. At present, abiraterone acetate is neither FDA-approved, nor commercially available. Johnson & Johnson will be providing abiraterone acetate free of charge to all study participants.  Eligible patients must have received 1 or 2 chemotherapy regimens (1 of which contained a taxane, such as docetaxel) and have progressive disease.

MAIMONIDES
MEDICAL CENTER


Home Page
Why Choose Us
Donations
Website Terms of Use
PATIENT
INFORMATION


Visitor & Patient Info
We Speak Your Language
Patient Privacy
Contact Us
KEY
INFORMATION


Find a Physician
Medical Services
Maimonides In the News
Directions & Parking
FOR HEALTH
PROFESSIONALS


Medical Education
Career Opportunities
Nurses & Physicians
Staff Intranet Access

Maimonides Medical Center    |    4802 Tenth Avenue    |    Brooklyn, NY 11219    |    718.283.6000